5. PRONOUNCE(A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease) was ongoing when we conducted our study. Characteristics were identified using https://t.co/yxwqaPuZfT
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @ICOSociety: We will be discussing the works of the article: https://t.co/IOs8LqFnGm Study design published in #JACCCardioOnc: https://…
RT @ICOSociety: We will be discussing the works of the article: https://t.co/IOs8LqFnGm Study design published in #JACCCardioOnc: https://…
RT @ICOSociety: We will be discussing the works of the article: https://t.co/IOs8LqFnGm Study design published in #JACCCardioOnc: https://…
RT @ICOSociety: We will be discussing the works of the article: https://t.co/IOs8LqFnGm Study design published in #JACCCardioOnc: https://…
RT @ICOSociety: We will be discussing the works of the article: https://t.co/IOs8LqFnGm Study design published in #JACCCardioOnc: https://…
RT @ICOSociety: We will be discussing the works of the article: https://t.co/IOs8LqFnGm Study design published in #JACCCardioOnc: https://…
RT @ICOSociety: We will be discussing the works of the article: https://t.co/IOs8LqFnGm Study design published in #JACCCardioOnc: https://…
We will be discussing the works of the article: https://t.co/IOs8LqFnGm Study design published in #JACCCardioOnc: https://t.co/8K0O5Az2cF #cardioonc @WondrMedical @PCFnews @OncoAlert @neerajaiims @Uroweb @CanUrolAssoc @CCardiacON
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
RT @JACCJournals: Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study des…
Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study design to learn more: https://t.co/n2WyYRPFRJ #CardioOnc #ASCVD #Degarelix #ProstateCancer #Leuprolide #PCsm @DukeHealth @DLBHATTMD http
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
RT @JACCJournals: Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy am…
Are you familiar with the PRONOUNCE trial? The study will be the first to compare MACE in androgen deprivation therapy among #prostatecancer patients treated w/ a GnRH antagonist vs. a GnRH agonist. Review in #JACCCardioOnc: https://t.co/jU1EEuuKvS #MHM202
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @jelevenson: Looking forward to this. @DrRobyT @Van_mugs @ABukariMD #CardioOnc https://t.co/i8EcFJrIMP
Looking forward to this. @DrRobyT @Van_mugs @ABukariMD #CardioOnc
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
RT @JACCJournals: #JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation…
#JACCCardioOnc details the trial design of PRONOUNCE, which will asses if #CVD events associated w/ androgen deprivation therapy are lower w/ a gonadotropin-releasing hormone (GnRH) antagonist vs. a GnRH agonist in men w/ pre-existing #ASCVD. https://t.co/
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
RT @ELS_Cardiology: Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design htt…
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design https://t.co/umbqEUIpJR @JACCJournals #CardioOnc #CardioOncology #CardioTwitter #SoMe https://t.co/O27dYVy95O